A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer

LESSONS LEARNED. In abiraterone‐ and/or enzalutamide‐refractory metastatic castration‐resistant prostate cancer (mCRPC) patients, selinexor led to prostate‐specific antigen and/or radiographic responses in a subset of patients, indicating clinical activity in this indication. Despite twice‐a‐week do...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xiao X., Siegel, Adam P., Aggarwal, Rahul, Lin, Amy M., Friedlander, Terence W., Fong, Lawrence, Kim, Won, Louttit, Mirela, Chang, Emily, Zhang, Li, Ryan, Charles J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067936/
https://www.ncbi.nlm.nih.gov/pubmed/29487219
http://dx.doi.org/10.1634/theoncologist.2017-0624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067936/
https://www.ncbi.nlm.nih.gov/pubmed/29487219
http://dx.doi.org/10.1634/theoncologist.2017-0624

Ejemplares similares